Physician profile
Mark D Anderson
NPI 1427021062
$3,833.26
in general payments reported to CMS, 2019-2025
11 companies · $56.41 in 2025
The $56.41 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $96.68 · 2021: $2,246 · 2022: $813 · 2023: $303 · 2024: $134 · 2025: $56.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,786.87 | 2019-2025 | Myday Contact Lens |
| Alcon Vision LLC | $270.40 | 2021-2024 | Total30, Precision 1 |
| Sun Pharmaceutical Industries INC. | $157.71 | 2020-2024 | Cequa |
| Abb Con-Cise Optical Group LLC | $147.22 | 2019-2022 | |
| Sight Sciences, INC. | $144.92 | 2022 | |
| Optos, INC. | $143.94 | 2022 | |
| Maculogix, INC. | $91.87 | 2021 | |
| Abbvie INC. | $28.84 | 2022 | |
| Biotissue Holdings INC. | $22.73 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $20.64 | 2024 | Xdemvy |
| Bausch & Lomb Americas INC. | $18.12 | 2024 | Infuse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.